Think about lifestyle change in terms of:
A move. A layoff. A break-up. A new job. A baby. An empty nest. Retirement.
Lifestyle change is hard, but it can be made easier with the right support.
The hard truth about long-term changes
Some changes we choose. Others, life hands to us without asking. But either way, we go in expecting effort—maybe even struggle. And because we expect that, we prepare. We gather resources. We call professionals. Read books. Ask for help. Save. The list goes on.
Not because the change is temporary, but because we plan to live in that change forever, and we have to be equipped for whatever comes our way during that period.
Cardiometabolic health, often starting with weight loss, is at its root a lifestyle change.
It requires planning. Commitment. Clear goals. And preparing for that adjustment often starts with the support we get through our health plan, and the provided care that comes with it.
Today, losing weight can be the easy part. Yes, you read that right. All you need is a prescription, a willing prescriber, and cash (or tap to pay.) Even if you’re just hoping to look small on your version of the red carpet, it can be as simple as medication once a week.
But here’s the problem we don’t talk about enough:
The popularization of rapid medication‑only weight loss has quietly reframed obesity care as a short‑term cosmetic fix rather than a long‑term health transition.
The “shortcut” mentality in modern metabolic care
Somewhere along the way, GLP-1s started being treated less like chronic disease medications and more like lifestyle accessories.
We’ve created a system where the medically underserved are being asked to jump through hoops, while the medically unnecessary can often pay to skip the line.
But these drugs aren’t harmless shortcuts like a can of dry shampoo on a greasy hair day; they require medical oversight, ongoing support, and a clear understanding of potential risks and side effects, including dehydration, muscle loss, nausea, the list goes on. It’s crucial for both the long- and short-term health of each patient that pharmaceutical interventions be paired with whole-person wraparound care.
There are important conversations to be had about access, affordability, and appropriate use of GLP-1s. But in the meantime, we should also be asking a different question:
How do we better support people when medication isn’t available, appropriate, or enough on its own?
That’s where the real care gap still exists.
Obesity stigma plays a role
There’s an uncomfortable reality beneath the surface: obesity has historically been underfunded, undertreated, and misunderstood within healthcare. Many patients already experience shame, dismissal, or delayed treatment when seeking care. Now, as these medications become culturally desirable, the conversation risks shifting even further away from chronic disease management and toward aesthetics and optimization.
That framing feeds stigma on both sides:
People who use GLP‑1 medications are told they’re “cheating.”
People who can’t access them are left with the message that they’ve failed.
And when medications are offered as the solution, rather than a tool, we shouldn’t be surprised by what happens next. The only thing “easier” than losing weight? Gaining it back once the medication stops—whether by choice, cost, side effects, or loss of access.
This isn’t a failure of the medication. It’s a failure of the proper solutions and support being offered in tandem.
Because when lifestyle change, mental health support, nutrition education, and movement are treated as optional add‑ons, rather than core components, we reinforce the idea that health is something you buy, not something you build.
And that deepens an already serious divide in health equity.
The commercialization of obesity care is widening access gaps
Access to GLP‑1 medications is stratified by income, insurance design, employer coverage, and geography. Those with resources can maintain pharmacologic support long‑term (or yo-yo between social events). At the same time, those without are more likely to cycle through weight loss and regain, absorbing the metabolic, psychological, and financial consequences of that cycle.
But the issue extends far beyond who does and does not get medication; it’s what happens after they do.
Sustainable health was never meant to hinge on a prescription alone. Weight loss may be the visible outcome, but lasting well-being is built through the quieter foundations of health: nourishing food, consistent sleep, movement, stress management, mental health support, and daily habits people can realistically sustain over time.
It is up to the employer to provide access to lifestyle change that transform your employee’s health—not just how their clothes fit.
So don’t just help your team members lose weight. Help them get resourced. Work on their mental health. Give them the option to talk to someone about the choices we make around food, movement, sleep, stress, meditation, and perception. (Yes—perception is a choice.)
And allow them the chance to talk not only about what they’ve lost, but what they’ve gained.
They’re stronger. Fitter. Calmer. Healthier.
The outcomes are tremendous, and the proof is in the numbers.
Quick Results, Long-Term Consequences
I need to emphasize that my perspective is not meant to be an expose around “GLP-1s and the dangers that be,” but rather a condensed look into the data that shows that while these medications can be effective tools when used properly, they can also be dangerous if we treat them as a one-size-fits-all solution.
Take, for instance, a Cleveland Clinic study of 460,000 adults prescribed a GLP-1 drug, nearly 1 in 5 developed a nutrient deficiency within a year, many without realizing it.
When GLP‑1–based medications are discontinued without sustained lifestyle support, most individuals regain a substantial portion of lost weight within one year.¹
Long‑term cardiometabolic improvements are more durable when pharmacotherapy is paired with behavioral and lifestyle intervention, rather than used alone.² ³
Weight stigma—including stigma tied to medication use—negatively affects mental health, healthcare engagement, and long‑term outcomes.⁶
Limited access to obesity pharmacotherapy exacerbates existing disparities in cardiometabolic disease, reinforcing inequities in diabetes, heart disease, and mortality.⁷ ⁸
And the list goes on.
So what’s your point, Annie?
I’m not saying you absolutely must “suffer through” without a GLP-1 to see stability in your metabolic health. Let me be clear: there are many cases in which GLP-1s are the appropriate path forward for certain patients, but there cannot be lasting change without proper care. Hard stop.
Weight loss is an outcome.
Health is the lifestyle you can sustain—and afford—to keep.
References
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. New England Journal of Medicine, 2022.
- Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA, 2021.
- American Diabetes Association. Standards of Care in Diabetes—Lifestyle Management. Diabetes Care, updated annually.
- The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New England Journal of Medicine, 2013.
- Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of heart disease. Circulation, 2019.
- Puhl RM, Himmelstein MS, Pearl RL. Weight stigma as a psychosocial contributor to obesity. American Psychologist, 2020.
- KFF (Kaiser Family Foundation). Insurance coverage and affordability of obesity medications, 2023.
- Brown JD, et al. Socioeconomic disparities in access to anti‑obesity pharmacotherapy. Obesity, 2022.
